Biolojic Design Appoints Neal Curran as Chief Business Officer By webadmin@biolojic.com|2024-12-08T11:53:30+00:00December 8, 2024|News|0 Comments Read More
Biolojic Design Joins Johnson & Johnson Innovation – JLABS By webadmin@biolojic.com|2024-12-08T11:52:48+00:00December 8, 2024|News|0 Comments Read More
A novel therapeutically active anti-TNFR2 agonistic antibody promotes Treg proliferation and induction of Treg functional markers By webadmin@biolojic.com|2024-08-06T09:42:32+00:00July 10, 2024|Publication|0 Comments Read More
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 By webadmin@biolojic.com|2024-06-25T13:25:24+00:00June 12, 2024|News|0 Comments Read More
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany. By webadmin@biolojic.com|2024-08-26T08:51:38+00:00June 3, 2024|News|0 Comments Read More
A Novel Computationally Designed Multibody Targeting IL-13/TSLP for Precision Therapy in TH2-Mediated Diseases By webadmin@biolojic.com|2024-08-06T09:35:51+00:00May 14, 2024|Publication|0 Comments Read More
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases By webadmin@biolojic.com|2024-06-05T12:40:33+00:00April 24, 2024|News|0 Comments Read More
Redirecting an anti-IL-1β antibody to bind a new, unrelated and computationally predicted epitope on hIL-17A By webadmin@biolojic.com|2024-08-13T11:38:01+00:00September 9, 2023|Publication|0 Comments Read More
Accurate profiling of full-length Fv in highly homologous antibody libraries using UMI tagged short reads By webadmin@biolojic.com|2024-08-26T08:57:55+00:00June 23, 2023|Publication|0 Comments Read More
Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2 By webadmin@biolojic.com|2024-08-26T08:53:18+00:00March 29, 2023|Publication|0 Comments Read More
